Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

OBJECTIVES:

Primary

• Research the oncogenetic parameters and pharmacogenetic and pharmacokinetic predictors of therapeutic response and toxic effects.

Secondary

• Study the correlations between the pharmacogenetic and pharmacokinetic parameters.
• Study the predictive value of these parameters on disease-free and overall survival.

OUTLINE: This is a multicenter study.

Patients receive 1 of 4 chemotherapy regimens:

• Regimen 1: Fluorouracil and leucovorin calcium
• Regimen 2: Capecitabine and leucovorin calcium
• Regimen 3: Irinotecan hydrochloride
• Regimen 4: Oxaliplatin Tumor and blood samples are collected before the start of chemotherapy and are examined by pharmacogenetic analysis. Clinical and biological parameters are also studied. Blood samples are also collected during the first course of chemotherapy for pharmacokinetic studies.

After completion of study therapy, patients are followed periodically for 3 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic colorectal cancer

• Unresectable metastatic disease must be confirmed histologically if > 2 years since primary diagnosis
• Measurable metastatic disease > 1 cm by spiral CT scan or > 2 cm by other methods
• Scheduled to receive first-line chemotherapy for metastatic disease

• Chemotherapy must include fluorouracil, capecitabine, irinotecan hydrochloride, or oxaliplatin
• No inadequate or unusable tissue as the only tissue available
• No known brain metastases or meningeal disease

PATIENT CHARACTERISTICS:

• WHO performance status 0-2
• No contraindication to chemotherapy
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No other severe pathology that is likely to worsen during therapy
• No dementia or severely impaired mental condition
• No geographical or psychological reasons that would preclude treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior therapy for metastatic cancer
• Prior adjuvant chemotherapy allowed
• Concurrent bevacizumab or other monoclonal antibody therapy allowed